Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of FURESTEM-AD Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis
Phase of Trial: Phase I/II
Latest Information Update: 31 Oct 2015
Price : $35 *
At a glance
- Drugs Umbilical cord mesenchymal stem cell therapy-Kangstem Biotech (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Kangstem Holdings
- 31 Aug 2018 Biomarkers information updated
- 31 Aug 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 17 Mar 2015 Planned End Date changed from 1 Dec 2014 to 1 Sep 2015 as reported by ClinicalTrials.gov record.